PD-L1 checkpoint inhibitor (Sorrento)

N/A

Report date: 2025/06/11 11:01:27

Base Information

Drug NamePD-L1 checkpoint inhibitor (Sorrento)
Drug Alias Nameanti-PD-L1 mAb (Sorrento)STI-A1010STI-A100XSTI-B010X
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsProgrammed death-ligand 1 blockersT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A